首页 > 最新文献

Movement Disorders Clinical Practice最新文献

英文 中文
Mouth Motor Overflow in Parkinson's Disease. 帕金森病的口腔运动溢出。
IF 2.7 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-02-02 DOI: 10.1002/mdc3.70548
Karim Makhoul, Joseph Jankovic

Background: Motor overflow phenomenon has been described in a variety of neurodegenerative conditions. Often referred to in the literature as "mirror" movements, this phenomenon actually represents a motor overflow, typically involving the contralateral limbs. This phenomenon has not been previously characterized in the facial or jaw muscles.

Objectives: We aim to describe the motor overflow phenomenon in orofacial muscles.

Methods: We examined videos of patients with Parkinson's disease (PD) from our video library who were undergoing standard OFF and ON assessments for deep brain stimulation evaluation for any evidence of involuntary movements in the face or mouth.

Results: Of the evaluated patients, 32% showed evidence of mouth motor overflow movements upon activation by rapid sequential movements (RSM) in the limbs.

Conclusion: In this study designed to systematically evaluate patients with PD for mouth motor overflow movements, we found that a third of the patients exhibited this phenomenon.

背景:运动溢出现象已在各种神经退行性疾病中被描述。通常在文献中被称为“镜像”运动,这种现象实际上代表了一种运动溢出,通常涉及对侧肢体。这种现象以前没有出现在面部或下颌肌肉中。目的:描述口面部肌肉的运动溢出现象。方法:我们检查了视频库中帕金森病(PD)患者的视频,这些患者正在进行标准的OFF和ON脑深部刺激评估,以评估面部或口腔的任何不自主运动的证据。结果:在被评估的患者中,32%的患者在肢体快速顺序运动(RSM)激活后表现出口腔运动溢出运动的证据。结论:本研究旨在系统评估PD患者的口腔运动溢出运动,我们发现三分之一的患者表现出这种现象。
{"title":"Mouth Motor Overflow in Parkinson's Disease.","authors":"Karim Makhoul, Joseph Jankovic","doi":"10.1002/mdc3.70548","DOIUrl":"https://doi.org/10.1002/mdc3.70548","url":null,"abstract":"<p><strong>Background: </strong>Motor overflow phenomenon has been described in a variety of neurodegenerative conditions. Often referred to in the literature as \"mirror\" movements, this phenomenon actually represents a motor overflow, typically involving the contralateral limbs. This phenomenon has not been previously characterized in the facial or jaw muscles.</p><p><strong>Objectives: </strong>We aim to describe the motor overflow phenomenon in orofacial muscles.</p><p><strong>Methods: </strong>We examined videos of patients with Parkinson's disease (PD) from our video library who were undergoing standard OFF and ON assessments for deep brain stimulation evaluation for any evidence of involuntary movements in the face or mouth.</p><p><strong>Results: </strong>Of the evaluated patients, 32% showed evidence of mouth motor overflow movements upon activation by rapid sequential movements (RSM) in the limbs.</p><p><strong>Conclusion: </strong>In this study designed to systematically evaluate patients with PD for mouth motor overflow movements, we found that a third of the patients exhibited this phenomenon.</p>","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adductor Respiratory Laryngeal Dystonia (Dystonic Respiratory Stridor): Clinical Characterization and Response to Botulinum Toxin Therapy: A Single Centre Experience. 内收肌呼吸性喉张力障碍(呼吸性喘鸣):临床特征和对肉毒杆菌毒素治疗的反应:单一中心经验。
IF 2.7 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-02-02 DOI: 10.1002/mdc3.70544
Owen Chan, Isabelle Osborne, Georgina Harris, Samuel Bolitho, Stephen Tisch

Background: Adductor respiratory laryngeal dystonia (ARLD) is a rare focal dystonia with vocal fold closure during inspiration leading to stridor and dyspnoea.

Objectives: To characterize clinical features and outcomes of patients with ARLD at a tertiary movement disorders center.

Methods: A retrospective cohort study was conducted of patients with adductor respiratory laryngeal dystonia attending a botulinum toxin injection clinic.

Results: Nineteen patients were identified. Most were female (94.7%). Mean age of onset was 51.9 years (range 39-89). Comorbid movement disorders included laryngeal dystonia, cervical dystonia, blepharospasm, dystonic tremor, and Parkinson's disease. Median time from symptom onset to diagnosis was 3.0 years (IQR 2.0-15.0). 92.8% of injections with botulinum toxin were effective, although 46.2% were associated with adverse events.

Conclusions: ARLD is associated with diagnostic delay. Symptoms of stridor alongside other movement disorders may provide clues. Treatment with botulinum toxin is effective, though careful dosing is required.

背景:内收肌呼吸性喉张力障碍(ARLD)是一种罕见的局灶性肌张力障碍,吸气时声带关闭,导致喘鸣和呼吸困难。目的:评价某三级运动障碍中心ARLD患者的临床特征和预后。方法:对在肉毒毒素注射诊所就诊的内收肌呼吸性喉张力障碍患者进行回顾性队列研究。结果:共发现19例患者。女性居多(94.7%)。平均发病年龄为51.9岁(39-89岁)。共病运动障碍包括喉肌张力障碍、颈肌张力障碍、眼睑痉挛、肌张力障碍震颤和帕金森病。从症状出现到诊断的中位时间为3.0年(IQR 2.0 ~ 15.0)。92.8%的注射肉毒杆菌毒素是有效的,尽管有46.2%的不良事件相关。结论:ARLD与诊断延迟有关。喘鸣和其他运动障碍的症状可能提供线索。用肉毒杆菌毒素治疗是有效的,但需要注意剂量。
{"title":"Adductor Respiratory Laryngeal Dystonia (Dystonic Respiratory Stridor): Clinical Characterization and Response to Botulinum Toxin Therapy: A Single Centre Experience.","authors":"Owen Chan, Isabelle Osborne, Georgina Harris, Samuel Bolitho, Stephen Tisch","doi":"10.1002/mdc3.70544","DOIUrl":"https://doi.org/10.1002/mdc3.70544","url":null,"abstract":"<p><strong>Background: </strong>Adductor respiratory laryngeal dystonia (ARLD) is a rare focal dystonia with vocal fold closure during inspiration leading to stridor and dyspnoea.</p><p><strong>Objectives: </strong>To characterize clinical features and outcomes of patients with ARLD at a tertiary movement disorders center.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted of patients with adductor respiratory laryngeal dystonia attending a botulinum toxin injection clinic.</p><p><strong>Results: </strong>Nineteen patients were identified. Most were female (94.7%). Mean age of onset was 51.9 years (range 39-89). Comorbid movement disorders included laryngeal dystonia, cervical dystonia, blepharospasm, dystonic tremor, and Parkinson's disease. Median time from symptom onset to diagnosis was 3.0 years (IQR 2.0-15.0). 92.8% of injections with botulinum toxin were effective, although 46.2% were associated with adverse events.</p><p><strong>Conclusions: </strong>ARLD is associated with diagnostic delay. Symptoms of stridor alongside other movement disorders may provide clues. Treatment with botulinum toxin is effective, though careful dosing is required.</p>","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146106259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analgesic Benefit of Low-Dose Foslevodopa/Foscarbidopa Infusion in Advanced Parkinson's Disease: A Non-Standard Therapeutic Application. 低剂量Foslevodopa/Foscarbidopa输注治疗晚期帕金森病的镇痛效果:非标准治疗应用
IF 2.7 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-02-02 DOI: 10.1002/mdc3.70550
Laura Kennelly, Brian Sweeney, Diana Angelika Olszewska
{"title":"Analgesic Benefit of Low-Dose Foslevodopa/Foscarbidopa Infusion in Advanced Parkinson's Disease: A Non-Standard Therapeutic Application.","authors":"Laura Kennelly, Brian Sweeney, Diana Angelika Olszewska","doi":"10.1002/mdc3.70550","DOIUrl":"https://doi.org/10.1002/mdc3.70550","url":null,"abstract":"","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146106317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PAS Congress Abstracts February 13, 2026. 国会摘要,2026年2月13日。
IF 2.7 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-02-01 DOI: 10.1002/mdc3.70478
{"title":"PAS Congress Abstracts February 13, 2026.","authors":"","doi":"10.1002/mdc3.70478","DOIUrl":"https://doi.org/10.1002/mdc3.70478","url":null,"abstract":"","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":"13 Suppl 1 ","pages":"S11-S129"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146180924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk of Falls and Need of Walking Aid in Parkinson's Disease: Incidence and Impact of Comorbidities. 帕金森病患者跌倒的风险和行走辅助的需要:共病的发生率和影响
IF 2.7 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-01-30 DOI: 10.1002/mdc3.70537
Louise-Laure Mariani, Benjamin Dano, Marion Houot, Graziella Mangone, Fernando Pico, Olivier Rascol, Ana Marques, Pascal Derkinderen, Marie Vidailhet, Alexis Brice, Jean-Christophe Corvol

Background: Predicting falls in patients with Parkinson's disease (PD) is challenging despite their significant frequency and consequences.

Objectives: To determine incidences of first fall, walking aid requirement, and identify risk factors of subsequent risk, including factors unrelated to PD.

Methods: Study in 415 PD patients (DIGPD prospective cohort). Cumulative incidence curves were calculated and Generalized Linear Mixed Models investigated influencing factors.

Results: Five years after diagnosis, 26.1% of patients experienced falls while only 2.1% required walking aids; after 10 years, it rose to 66.5% and 17%, respectively. Median time to first fall was 7.9 years. Risk factors of falls were cognitive decline, freezing, comorbidities such as diabetes and depression, history of falls particularly in male, or low Body Mass Index (BMIs). Walking aids risk factors were older age, freezing, lower walking speed, higher BMIs, history of walking aid.

Conclusions: Treatable comorbidities (depression, diabetes, weight regulation) should be addressed in daily care to avoid falls in PD patients.

背景:预测帕金森病(PD)患者的跌倒是具有挑战性的,尽管其频率和后果显著。目的:确定首次跌倒的发生率、行走辅助需求,并确定后续风险因素,包括与PD无关的因素。方法:对415例PD患者(DIGPD前瞻性队列)进行研究。计算累积入射曲线,研究广义线性混合模型的影响因素。结果:确诊5年后,26.1%的患者发生跌倒,仅2.1%的患者需要助行器;10年后,这一比例分别升至66.5%和17%。第一次跌倒的平均时间是7.9年。跌倒的危险因素包括认知能力下降、身体冻结、合并症(如糖尿病和抑郁症)、跌倒史(尤其是男性)或低身体质量指数(bmi)。助行器的危险因素为年龄较大、结冰、行走速度较慢、bmi较高、有助行器史。结论:PD患者在日常护理中应注意可治疗的合并症(抑郁、糖尿病、体重调节),以避免跌倒。
{"title":"Risk of Falls and Need of Walking Aid in Parkinson's Disease: Incidence and Impact of Comorbidities.","authors":"Louise-Laure Mariani, Benjamin Dano, Marion Houot, Graziella Mangone, Fernando Pico, Olivier Rascol, Ana Marques, Pascal Derkinderen, Marie Vidailhet, Alexis Brice, Jean-Christophe Corvol","doi":"10.1002/mdc3.70537","DOIUrl":"https://doi.org/10.1002/mdc3.70537","url":null,"abstract":"<p><strong>Background: </strong>Predicting falls in patients with Parkinson's disease (PD) is challenging despite their significant frequency and consequences.</p><p><strong>Objectives: </strong>To determine incidences of first fall, walking aid requirement, and identify risk factors of subsequent risk, including factors unrelated to PD.</p><p><strong>Methods: </strong>Study in 415 PD patients (DIGPD prospective cohort). Cumulative incidence curves were calculated and Generalized Linear Mixed Models investigated influencing factors.</p><p><strong>Results: </strong>Five years after diagnosis, 26.1% of patients experienced falls while only 2.1% required walking aids; after 10 years, it rose to 66.5% and 17%, respectively. Median time to first fall was 7.9 years. Risk factors of falls were cognitive decline, freezing, comorbidities such as diabetes and depression, history of falls particularly in male, or low Body Mass Index (BMIs). Walking aids risk factors were older age, freezing, lower walking speed, higher BMIs, history of walking aid.</p><p><strong>Conclusions: </strong>Treatable comorbidities (depression, diabetes, weight regulation) should be addressed in daily care to avoid falls in PD patients.</p>","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146086430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Refractory Motor Complications: Towards a Pragmatic Definition. 难治性运动并发症:走向实用定义。
IF 2.7 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-01-30 DOI: 10.1002/mdc3.70542
Georg Ebersbach, Tobias Warnecke
{"title":"Refractory Motor Complications: Towards a Pragmatic Definition.","authors":"Georg Ebersbach, Tobias Warnecke","doi":"10.1002/mdc3.70542","DOIUrl":"https://doi.org/10.1002/mdc3.70542","url":null,"abstract":"","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146086412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors Associated with Early Discontinuation of Foslevodopa/Foscarbidopa in Parkinson's Disease. 帕金森病患者早期停用Foslevodopa/Foscarbidopa的相关因素
IF 2.7 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-01-30 DOI: 10.1002/mdc3.70545
Keita Kakuda, Yasuyoshi Kimura, Lindun Ge, Kensuke Ikenaka, Kanako Asai, Shunpei Murakami, Kotaro Ogawa, Hideki Mochizuki
{"title":"Factors Associated with Early Discontinuation of Foslevodopa/Foscarbidopa in Parkinson's Disease.","authors":"Keita Kakuda, Yasuyoshi Kimura, Lindun Ge, Kensuke Ikenaka, Kanako Asai, Shunpei Murakami, Kotaro Ogawa, Hideki Mochizuki","doi":"10.1002/mdc3.70545","DOIUrl":"https://doi.org/10.1002/mdc3.70545","url":null,"abstract":"","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146086445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Constructing Neurology: Jean-Martin Charcot (1825-1893): A Bicentenary Tribute. 建构神经学:让-马丁·夏科(1825-1893):200周年纪念。
IF 2.7 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-01-30 DOI: 10.1002/mdc3.70538
Christian Riederer, Christopher G Goetz, Olivier Walusinski

Objective: To honor the bicentenary of Jean-Martin Charcot's birth and to consolidate the primary materials from a historical exhibit on the topic at the 2025 International Parkinson and Movement Disorder Congress, this article aims to provide an overview of Charcot's place in the context of 21st century movement disorders neurology.

Background: Charcot (1825-1893) is largely considered the Father of Clinical Neurology, having established the basic discipline of anatomo-clinical correlations in brain and spinal cord disease. His contributions to movement disorders neurology were seminal and remain as anchors of 21st century neurological study.

Methods: Original and secondary sources from international archives and collections served as the material for study and interpretation.

Results: Charcot fundamentally contributed to the clinical descriptions of Parkinson's disease, other parkinsonian syndromes, tremor conditions, tic disorders and chorea. Whereas he performed extensive neuroanatomical studies, he classified most movement disorders as névroses, conditions with undetected structural lesions yet to be defined.

Conclusions: Charcot developed a clear classification system for movement disorders that largely remains intact today. He developed a French School of Neurology of both historical and modern fame, and, in introducing the model of an academic clinical hospital research center as multidimensional integration of clinical care, research, and education, he left a legacy that remains the model of the 21st century neurological research center.

目的:为了纪念Jean-Martin Charcot诞辰200周年,并整合2025年国际帕金森与运动障碍大会上关于该主题的历史展览的主要材料,本文旨在概述Charcot在21世纪运动障碍神经病学中的地位。背景:Charcot(1825-1893)被广泛认为是临床神经学之父,他建立了脑和脊髓疾病解剖-临床相关性的基本学科。他对运动障碍神经学的贡献是开创性的,并且仍然是21世纪神经学研究的支柱。方法:以国际档案和收藏的原始和二手资料为研究和解释材料。结果:Charcot对帕金森病、其他帕金森综合征、震颤病症、抽动障碍和舞蹈病的临床描述做出了根本性的贡献。尽管他进行了广泛的神经解剖学研究,但他将大多数运动障碍归类为未被发现的结构损伤尚未被定义的疾病。结论:Charcot为运动障碍建立了一个清晰的分类系统,该系统在很大程度上保留至今。他创立了法国神经病学学派,在历史上和现代都享有盛誉。他将学术性临床医院研究中心的模式引入临床护理、研究和教育的多维整合中,留下了21世纪神经学研究中心的典范。
{"title":"Constructing Neurology: Jean-Martin Charcot (1825-1893): A Bicentenary Tribute.","authors":"Christian Riederer, Christopher G Goetz, Olivier Walusinski","doi":"10.1002/mdc3.70538","DOIUrl":"https://doi.org/10.1002/mdc3.70538","url":null,"abstract":"<p><strong>Objective: </strong>To honor the bicentenary of Jean-Martin Charcot's birth and to consolidate the primary materials from a historical exhibit on the topic at the 2025 International Parkinson and Movement Disorder Congress, this article aims to provide an overview of Charcot's place in the context of 21st century movement disorders neurology.</p><p><strong>Background: </strong>Charcot (1825-1893) is largely considered the Father of Clinical Neurology, having established the basic discipline of anatomo-clinical correlations in brain and spinal cord disease. His contributions to movement disorders neurology were seminal and remain as anchors of 21st century neurological study.</p><p><strong>Methods: </strong>Original and secondary sources from international archives and collections served as the material for study and interpretation.</p><p><strong>Results: </strong>Charcot fundamentally contributed to the clinical descriptions of Parkinson's disease, other parkinsonian syndromes, tremor conditions, tic disorders and chorea. Whereas he performed extensive neuroanatomical studies, he classified most movement disorders as névroses, conditions with undetected structural lesions yet to be defined.</p><p><strong>Conclusions: </strong>Charcot developed a clear classification system for movement disorders that largely remains intact today. He developed a French School of Neurology of both historical and modern fame, and, in introducing the model of an academic clinical hospital research center as multidimensional integration of clinical care, research, and education, he left a legacy that remains the model of the 21st century neurological research center.</p>","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146093080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abdominal Segmental Myoclonus Resembling Belly Dancer Dyskinesia: An Autopsy-Proven Case. 腹部节段性肌阵挛类似于肚皮舞者运动障碍:一个尸检证实的病例。
IF 2.7 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-01-29 DOI: 10.1002/mdc3.70546
Yuki Takeda, Yoshikatsu Noda, Munenori Iwamoto, Kakuya Nagata, Yoshimitsu Shimatani, Shuichi Tsukamoto, Yukihiro Imai, Hiroyuki Ishihara
{"title":"Abdominal Segmental Myoclonus Resembling Belly Dancer Dyskinesia: An Autopsy-Proven Case.","authors":"Yuki Takeda, Yoshikatsu Noda, Munenori Iwamoto, Kakuya Nagata, Yoshimitsu Shimatani, Shuichi Tsukamoto, Yukihiro Imai, Hiroyuki Ishihara","doi":"10.1002/mdc3.70546","DOIUrl":"https://doi.org/10.1002/mdc3.70546","url":null,"abstract":"","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146086406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reduced Dopamine Transporter Uptake in Dentatorubral-Pallidoluysian Atrophy. 齿状体-苍白球萎缩中多巴胺转运蛋白摄取减少。
IF 2.7 4区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2026-01-27 DOI: 10.1002/mdc3.70541
Kei Okuba, Shugo Fujita, Hitoshi Kawasaki, Genko Oyama
{"title":"Reduced Dopamine Transporter Uptake in Dentatorubral-Pallidoluysian Atrophy.","authors":"Kei Okuba, Shugo Fujita, Hitoshi Kawasaki, Genko Oyama","doi":"10.1002/mdc3.70541","DOIUrl":"https://doi.org/10.1002/mdc3.70541","url":null,"abstract":"","PeriodicalId":19029,"journal":{"name":"Movement Disorders Clinical Practice","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146053194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Movement Disorders Clinical Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1